Liangzhi Xie

16PUBLICATIONS
23CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Innate immunityMolecular targetsIntensive carePharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Sep 08, 2026
Phase Ib Trial of Finotonlimab Combined With SCT200 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.

|Sep 27, 2025
Baseline Anti-SARS-CoV-2 IgG and Protection from Symptomatic Infection: Post Hoc Analysis of the SCTV01E Phase 3 Randomized Trial.

Lixin Yan, Jiang Yi, Dongfang Liu

|Aug 06, 2025
Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial.

Chuanhua Zhao, Yanqiao Zhang, Gang Wang

|Jul 17, 2025
Immunogenicity of monovalent and multivalent subunit vaccines against SARS-CoV-2 variants in mice with divergent vaccination history.

Rui Wang, Yuan Lyu, Meng Chen

|May 07, 2025
Fc-Modified Antibody in Hospitalized Severe COVID-19 Patients.

Felipe Dal-Pizzol, Suzana Margareth Lobo, Christopher Lucasti

|Mar 27, 2025
Preclinical Characterization of Efficacy and Pharmacodynamic Properties of Finotonlimab, a Humanized Anti-PD-1 Monoclonal Antibody.

Yunqi Yao, Xiaoning Yang, Jing Li

Pageof 3

Frequent Collaborators

3 joint publications

Suad Hannawi

3 joint publications

Alaa Abuquta

2 joint publications

Linda Saf Eldin

2 joint publications

Sally A Mahmoud